| Literature DB >> 21459328 |
Shay Porat1, Noa Weinberg-Corem2, Sharona Tornovsky-Babaey3, Rachel Schyr-Ben-Haroush4, Ayat Hija2, Miri Stolovich-Rain2, Daniela Dadon2, Zvi Granot2, Vered Ben-Hur5, Peter White6, Christophe A Girard7, Rotem Karni5, Klaus H Kaestner6, Frances M Ashcroft7, Mark A Magnuson8, Ann Saada9, Joseph Grimsby10, Benjamin Glaser11, Yuval Dor12.
Abstract
Recent studies revealed a surprising regenerative capacity of insulin-producing β cells in mice, suggesting that regenerative therapy for human diabetes could in principle be achieved. Physiologic β cell regeneration under stressed conditions relies on accelerated proliferation of surviving β cells, but the factors that trigger and control this response remain unclear. Using islet transplantation experiments, we show that β cell mass is controlled systemically rather than by local factors such as tissue damage. Chronic changes in β cell glucose metabolism, rather than blood glucose levels per se, are the main positive regulator of basal and compensatory β cell proliferation in vivo. Intracellularly, genetic and pharmacologic manipulations reveal that glucose induces β cell replication via metabolism by glucokinase, the first step of glycolysis, followed by closure of K(ATP) channels and membrane depolarization. Our data provide a molecular mechanism for homeostatic control of β cell mass by metabolic demand.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21459328 DOI: 10.1016/j.cmet.2011.02.012
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287